Immunome Inc. Insider SIEGALL CLAY B Bought About $1.2M During December 2025

SIEGALL CLAY B bought about $1.2M of IMNM during December 2025.

That matters because open-market buying usually carries more signal than routine award or withholding activity.

What Happened

Date	Code	Shares	Price	Estimated Value
2025-12-30	P	4,729	$21.15	$100K
2025-12-19	P	7,278	$20.48	$149K
2025-12-18	P	46,511	$21.50	$1000K

The visible cluster added up to about 59K shares at an average transaction price near $21.34. In practice, that makes this a useful buy-window read rather than a one-line Form 4 anecdote.

Why This Window Matters

SIEGALL CLAY B shows up here as a officer, director tied to Immunome Inc.. That matters because the market reads insider trading differently depending on whether the actor is running the business, overseeing it from the board, or controlling a large outside stake.

What matters most is not just that a trade happened. It is whether the sizing, repetition, and ownership-after pattern change how investors should read alignment.

Ownership Context

The latest visible transaction reported 665K shares after the trade. That keeps the story anchored in cadence and sizing rather than a full direct-position exit.

Signal Check

This is not proof of a full thesis change by itself. It is evidence that capital actually moved in the open market, which is why readers should compare it with the next filing rather than overreact to a single day.

For more context on how institutional portfolios can still hide concentration under a long tail, compare this news item with the related research hub and the learn guide on 13F comparison.

What to Watch

• IMNM follow-through: whether the stock keeps validating the insider's buy timing.
• Position sizing: whether the insider adds again or treats this as a single signal purchase.
• Ownership trend: whether the reported stake continues to build over the next filings.
• Catalyst path: whether company-specific updates justify the fresh buying window.